Characteristics of patients studied
| . | Obtained medical marijuana (A) . | Did not obtain medical marijuana (B) . | Did not request certification (C) . | P (AB) . | P (AC) . | P (BC) . |
|---|---|---|---|---|---|---|
| N | 29 | 21 | 25 | |||
| Age, y | 30.9 ± 7.6 | 34.4 ± 13.1 | 36.3 ± 12.8 | .3 | .1 | .3 |
| Sex, % male | 59 | 38 | 36 | .08 | .06 | .5 |
| Hydroxyurea use, % | 48 | 33 | 44 | .2 | .3 | .3 |
| Private insurance, % | 24 | 14 | 40 | .2 | .08 | .02 |
| Previous cannabinoid positive toxicology, % | 79 | 69 | 6 | .3 | <.001 | <.001 |
| Previous admissions (/6 mo) | 1.0 (0.0/2.0) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | .1 | .4 | .2 |
| Previous ED use (/6 mo) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | .4 | .4 | .3 |
| Previous infusion center use (/6 mo) | 0.0 (0.0/0.0) | 0.0 (0.0/1.0) | 0.0 (0.0/0.0) | .1 | .4 | .2 |
| Previous total utilization | 1.0 (0.0/3.0) | 1.0 (0.0/2.0) | 1.0 (0.0/2.0) | .2 | .1 | .4 |
| Previous daily opioids (OME) | 19.7 (2.5/266.3) | 18.7 (1.8/180.0) | 0.6 (0.0/4.5) | .4 | .002 | <.001 |
| Change in admissions | 0.0 (-1.0/0.0) | 0.0 (0.0/1.0) | 0.0 (-0.5/0.0) | .02 | .1 | .2 |
| Change in ED use | 0.0 (0.0/0.0) | 0.0 (0.0/1.0) | 0.0 (-0.5/0.0) | .4 | .1 | .08 |
| Change in infusion center use | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | .2 | .4 | .3 |
| Change in total utilization | 0.0 (-1.0/1.0) | 0.0 (-1.0/2.0) | 0.0 (0.0/0.5) | .2 | .4 | .3 |
| Change in daily opioids (OME) | 0.0 (-1.7/4.0) | 0.0 (-2.3/10.0) | 0.0 (0.0/2.6) | .4 | .1 | .2 |
| . | Obtained medical marijuana (A) . | Did not obtain medical marijuana (B) . | Did not request certification (C) . | P (AB) . | P (AC) . | P (BC) . |
|---|---|---|---|---|---|---|
| N | 29 | 21 | 25 | |||
| Age, y | 30.9 ± 7.6 | 34.4 ± 13.1 | 36.3 ± 12.8 | .3 | .1 | .3 |
| Sex, % male | 59 | 38 | 36 | .08 | .06 | .5 |
| Hydroxyurea use, % | 48 | 33 | 44 | .2 | .3 | .3 |
| Private insurance, % | 24 | 14 | 40 | .2 | .08 | .02 |
| Previous cannabinoid positive toxicology, % | 79 | 69 | 6 | .3 | <.001 | <.001 |
| Previous admissions (/6 mo) | 1.0 (0.0/2.0) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | .1 | .4 | .2 |
| Previous ED use (/6 mo) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | 0.0 (0.0/1.0) | .4 | .4 | .3 |
| Previous infusion center use (/6 mo) | 0.0 (0.0/0.0) | 0.0 (0.0/1.0) | 0.0 (0.0/0.0) | .1 | .4 | .2 |
| Previous total utilization | 1.0 (0.0/3.0) | 1.0 (0.0/2.0) | 1.0 (0.0/2.0) | .2 | .1 | .4 |
| Previous daily opioids (OME) | 19.7 (2.5/266.3) | 18.7 (1.8/180.0) | 0.6 (0.0/4.5) | .4 | .002 | <.001 |
| Change in admissions | 0.0 (-1.0/0.0) | 0.0 (0.0/1.0) | 0.0 (-0.5/0.0) | .02 | .1 | .2 |
| Change in ED use | 0.0 (0.0/0.0) | 0.0 (0.0/1.0) | 0.0 (-0.5/0.0) | .4 | .1 | .08 |
| Change in infusion center use | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | .2 | .4 | .3 |
| Change in total utilization | 0.0 (-1.0/1.0) | 0.0 (-1.0/2.0) | 0.0 (0.0/0.5) | .2 | .4 | .3 |
| Change in daily opioids (OME) | 0.0 (-1.7/4.0) | 0.0 (-2.3/10.0) | 0.0 (0.0/2.6) | .4 | .1 | .2 |
Parametric data presented as mean ± standard deviation. Nonparametric data presented as quartiles 50% (25%/75%).
OME, oral morphine equivalents.